Rheumatologists’ Interest in Sotyktu Surges for Psoriatic Arthritis
Bristol Myers Squibb (BMS) announced positive topline results from Phase 3 trials of Sotyktu (deucravacitinib) for psoriatic arthritis (PsA)....
Jon Napitupulu
Urteste’s Pancreatic Cancer Test Trials in Europe Q3 2025
Urteste S.A., a Polish company specializing in early cancer detection through urine analysis, plans to start clinical trials for...
Chemomab’s PSC Trial Shows Positive Liver Biomarker Results
Chemomab Therapeutics announced positive 48-week data from the open-label extension (OLE) of its Phase 2 SPRING trial for nebokitug...
Candel Therapeutics Reports Prolonged Overall Survival in Phase 2a Trial of CAN-2409 in Advanced NSCLC
Candel Therapeutics announced final survival data from a Phase 2a clinical trial of CAN-2409 in patients with advanced non-small...
Rani Therapeutics Announces Bioequivalence of Oral GLP-1/GLP-2 Dual Agonist RT-114
Rani Therapeutics announced positive preclinical data for RT-114, an oral formulation of ProGen’s GLP-1/GLP-2 dual agonist, PG-102, for obesity...
Nephrologists Embrace Aggressive IgA Nephropathy Treatment
Spherix’s recent study of 507 IgA nephropathy (IgAN) patients reveals a disconnect between treatment goals and real-world disease management,...
Sonnet Biotherapeutics’ SON-1010 Shows Promising Safety in Sarcoma Combination Trial
Sonnet BioTherapeutics announced positive safety data from an expansion cohort of its Phase 1 SB101 trial. The trial is...
Decoy Therapeutics’ Novel Inhibitors Show Promise Against Measles
Decoy Therapeutics, a preclinical biopharmaceutical company, has announced that its antiviral drug candidates, designed using its IMP3ACT™ platform, have...
Acu193 Alzheimer’s Trial Enrollment Complete
Acumen Pharmaceuticals has completed enrollment in its Phase 2 ALTITUDE-AD trial of sabirnetug (ACU193) for early-stage Alzheimer’s diseaseAlzheimer’s disease....
City of Hope & Calidi Biotherapeutics Phase 1 Trial Update on CLD-101
Calidi Biotherapeutics and City of Hope announced positive progress in a Phase 1 clinical trial for CLD-101, a neural...